Novo Nordisk | NVO - Capital De Empréstimo





Capital De Empréstimo Alterar Data
ANI Pharmaceuticals USD 286M 5.84M 2026-03
Aurora Cannabis CAD 33.2M 1.79M 2025-12
Bausch Health Companies USD 19.9B 720M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Canopy Growth CAD 224.99M 1.34M 2025-12
Drreddys Laboratories INR 129.19M 1.84M 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Merck USD 46.67B 77M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Novartis USD 37.45B 7.86B 2026-03
Novo Nordisk DKK 119.17B 231M 2026-03
Novo Nordisk DKK 14.02B 224.49M 2025-09
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.62B 17.5M 2026-03
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 1.05B 39.73M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
Supernus Pharmaceuticals USD 400.38M 21.13M 2022-03
Zoetis USD 9.04B 3M 2026-03